Contract Pharma Manufacturing News

  1. Cambrex Expands Peptide Manufacturing Capabilities In Waltham, Massachusetts 8/25/2025

    Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts to further support the development and manufacturing of peptide therapies.

  2. Johnson & Johnson Continues U.S. Investment With $2B Commitment To Enable Manufacturing At State-Of-The-Art North Carolina Facility 8/21/2025

    Johnson & Johnson (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced today it will increase its presence in North Carolina with a 160,000+ square foot dedicated manufacturing facility at FUJIFILM’s new biopharmaceutical manufacturing site in Holly Springs, North Carolina.

  3. Andelyn Biosciences And Amplo Biotechnology Partner To Manufacture Novel Gene Therapies For Diseases Affecting The Neuromuscular Junction 8/21/2025

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Amplo Biotechnology, a pioneer in adeno-associated virus (AAV) regenerative medicines for neuromuscular junction (NMJ) affecting conditions.

  4. Piramal Pharma Solutions And NewAmsterdam Pharma Invest In Dedicated Suite To Enhance Oral Solid Dosage Production Capabilities At Piramal's Sellersville, Pennsylvania Site 8/21/2025

    Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA.

  5. Jazz Pharmaceuticals Enters Exclusive Licensing Agreement With Saniona To Develop And Commercialize SAN2355 8/20/2025

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Saniona (Nasdaq OMX: SANION) today announce that the companies have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other potential indications, designed to overcome the limitations of non-selective Kv7-targeting compounds.

  6. ACROBiosystems And DAAN Biotherapeutics Sign Strategic MOU For The Development Of Precision Immuno-Oncology Therapeutics 8/20/2025

    ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutics, a clinical-stage biotech focused on precision immuno-oncology therapeutics.

  7. Boehringer Ingelheim And AnGes Sign Manufacturing Agreement For HGF Gene Therapy Product 8/20/2025

    Boehringer Ingelheim is pleased to announce the signing of a contract development and manufacturing agreement with AnGes Inc. for the drug substance of AnGes' investigational treatment for Peripheral Arterial Disease (PAD).

  8. ProMed Pharma Announces Acquisition Of Manufacturing Facility From Bora Pharmaceuticals 8/19/2025

    ProMed Pharma LLC, a leading provider of polymer-based drug delivery solutions, today announced the acquisition of a 28,000 square foot, state-of-the-art pharmaceutical manufacturing facility located at 2200 N Niagara Lane, Plymouth, Minnesota.

  9. Battelle And Aprecia Collaborate With U.S. Department Of Health And Human Services And U.S. Defense Advanced Research Projects Agency To Advance U.S. Drug Manufacturing Capability Utilizing 3D-Printed Technology To Produce Essential Medicines At The Point 8/19/2025

    Battelle and Aprecia have been awarded a U.S. Defense Advanced Research Projects Agency (DARPA) agreement to advance the research program titled Establishing Qualification Processes for Agile Pharmaceutical Manufacturing (EQUIP-A-Pharma) through funding from the U.S. Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR) Office of Industrial Base Management and Supply Chain (IBMSC). ASPR's mission is to assist in preparing for, responding to, and recovering from public health emergencies and disasters.

  10. Skyhawk Therapeutics Announces Strategic Collaboration With Merck KGaA, Darmstadt, Germany To Discover Novel RNA-Targeting Small Molecules For Neurological Disorders 8/18/2025

    Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.